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overzichtsartikel
samenvatting  De ontwikkeling van geneesmiddelen waarmee opioïd-geïnduceerde 
ademhalingsdepressie (OIRD) kan worden voorkomen of behandeld blijft een grote 
uitdaging. Alhoewel er door de jaren aan een groot aantal stoffen een ademhaling 
stimulerend effect is toegeschreven, bleek het gebruik in de klinische praktijk beperkt 
door een smalle therapeutische breedte of door ernstige bijwerkingen. Sinds de 
introductie van naloxon is er een veilige behandeling voor OIRD. Naloxon antagoneert 
echter alle opioïdeffecten, waaronder ook het gewenste analgetische effect. Dit maakt 
naloxon weliswaar zeer nuttig voor de behandeling van levensbedreigende OIRD, maar 
het is ongeschikt als preventief middel. Recentelijk is aangetoond dat ampakines en 
kalium-kanaal blokkers zoals GAL021 ademdepressie door opioïden kunnen voorkomen 
zonder de analgetische werking te beïnvloeden en zonder ernstige bijwerkingen. In de 
komende jaren kunnen deze ademhalingsstimulantia een waardevolle aanvulling vormen 
op het arsenaal van de anesthesioloog.
abstract  The development of respiratory stimulants and opioid antagonists to 
treat opioid induced respiratory depression remains one of the biggest challenges in 
respiratory research. A variety of substances with stimulatory effects on respiration have 
been shown to be of little use in clinical practice, either because of narrow margins of 
safety or due to serious side effects. With the introduction of naloxone a safe treatment 
for OIRD came within reach, although it reverses all opioid effects, thereby also affecting 
analgesia. This makes naloxone a very useful drug to treat life-threatening OIRD, but not 
efficacious for prevention of OIRD. Recent studies have shown that the development 
of ampakines and potassium-channel blockers such as GAL021 make prevention of 
OIRD without incidence of serious side effects possible. In the forthcoming years these 
respiratory stimulants might become a valuable addition to the anesthesiologists’ 
armamentarium.   
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Introduction
In humans, ventilation is driven by 
a complex physiological system that 
relies critically on intact peripheral 
and central chemosensors, a variety 
of interacting respiratory centers in 
the brainstem and higher brain cent-
ers. The system makes use of feedback 
and feed forward control aimed at 
maintaining rhythmic breathing and 
ensuring rapid adaptations to behav-
ioral changes (such as eating, drink-
ing, and exercising). In early years 
of anesthesia, with the introduction 
of chloroform and ether, respiratory 
depression was a major cause of mor-
bidity and mortality, not only during 
surgery but also long after cessation of 
the procedure [1]. The high incidence 
of respiratory events prompted the 
pharmaceutical industry and anes-
thesia community to develop and use 
safer anesthetics, construct devices to 
protect and monitor ventilation and 
install measures that reduce the devas-
tating sequels of severe respiratory de-
pression (for example intubation and 
artificial ventilation). In modern anes-
thesia practice, respiratory depression, 
mainly opioid-induced respiratory 
depression (OIRD) remains an impor-
tant issue, specifically when potent 
respiratory depressants are used under 
circumstances of reduced or minimal 
monitoring. One possible way to ad-
dress or prevent respiratory depres-
sion from opioids or other agents is to 
administer respiratory stimulants that 
will reduce the probability of res-
piratory events without affecting the 
wanted end-points of drug treatment 
such as analgesia.
Until recently, research into respira-
tory stimulants was largely unsuccess-
ful. Drugs that were developed either 
displayed severe adverse events, or the 
results in the preclinical setting could 
not be extrapolated to clinical prac-
tice. Moreover, respiratory stimulation 
is often a coincidental side effect of 
drugs developed for other indications. 
Current research that makes use of the 
recent insights in molecular pathways 
of the ventilatory control system led 
to the development of promising 
molecules that effectively reverse or 
prevent OIRD with minimal side ef-
fects. Examples are the ampakines (e.g. 
CX717) and potassium-channel block-
ers (e.g. GAL021). These new molecules 
possibly can reduce the occurrence of 
OIRD both in the perioperative set-
ting as well as in chronic pain manage-
ment with potent opioids. 
Here we provide a short overview of 
respiratory stimulants that were used 
in the past and give a short impression 
of newly developed molecules.  
The use of respiratory  
stimulants long time ago
Carbon Dioxide (CO2)
The first experiments with CO2 on hu-
man subjects were performed by Hal-
dane and Priestly in the beginning of 
the 20th century in Oxford (see Figure 
1) [2]. These experiments evaluated the 
effects of varying alveolar concentra-
tions of CO2 at different atmospheric 
pressures, fluctuating concentrations 
of oxygen and various levels of physi-
cal exercise to test their – at that time 
novel – hypothesis that CO2 partial 
pressure (pCO2) in the respiratory 
center was the main driving force of 
ventilation. This hypothesis was based 
on earlier work by Haldane and Lor-
rain Smith in the 19th century; they 
studied possible reasons for the high 
death rates in overcrowded dwellings 
[3]. They concluded that the increase 
in ventilation caused by the increase 
in the level of CO2 was similar to the 
tachypnea during physical exercise, 
while the increase in ventilation 
caused by depletion of oxygen was 
distinctly different, since hypoxia 
produced subjective sensations of 
cyanosis [3]. 
By identifying alveolar pCO2 as the 
most important factor driving respi-
ration and affirming that changes in 
pCO2 were transferred to the respira-
tory center through arterial blood 
instead of via vagal or sympathetic 
stimulation of the respiratory center, 
Haldane and Priestly dramatically 
changed the way respiratory regula-
tion was perceived. They concluded 
that the respiratory center attunes 
to changes in arterial PCO2 (PaCO2). 
Elevating PaCO2 increases ventila-
tion drastically, whereas decreases in 
PaCO2 will eventually lead to apnea 
[2]. Although a potent stimulant, 
CO2 has been of little practical use by 
itself to treat opioid induced respira-
tory depression. It has been used to 
coerce the anesthetized patients into 
hyperventilation in order to rapidly 
exhale inhaled anesthetics [4]. But the 
practice of pouring 100% CO2 over the 
face, for several breaths, did not be-
come common practice. Reservations 
to use CO2 as a respiratory stimulant 
were caused by the notion that an 
increase in PaCO2 would cause depres-
sion of the central nervous system. 
This idea originated from research in 
the early 19th century when Hickman 
first successfully induced CO2 narcosis 
in animals (an experiment designed 
to prove that CO2 may be used in 
Figure 1. Body plethysmograph used by Haldane and Priestly (1905). All experimentations were 
performed on the authors themselves. Elevation of partial pCO2 was achieved by placing a 
sealed wooden box over the head. From Ref. 2.
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humans for anesthesia as well) [6]. 
Further research on acute exposure 
to CO2 showed that exposure to 10.4 
% CO2 produced a profound increase 
in ventilation approaching maximal 
voluntary ventilation, as well as a de-
creased level of consciousness in some 
subjects [7]. A case-report of a patient 
with muscular dystrophy suffering 
from respiratory failure and an altered 
state of consciousness attracted much 
attention [8]. The PaCO2 measured in 
this patient was approximately 8 kPa, 
which became the upper limit above 
which CO2 narcosis would likely oc-
cur. Recent, unpublished data from 
our laboratory show that CO2 expo-
sure of 9 and 10% (up to 1 h) in healthy 
male volunteers causes attentional 
narrowing and agitation apart from 
extensive respiratory stimulation; CO2 
induced narcosis was not observed [9].
Atropine
Atropine is a substance long thought 
to have a stimulatory effect on respira-
tion. Data regarding such an effect 
however are at best ambiguous. A 
first study published in 1914 found 
that atropine produced an increase in 
minute volume of approximately 15% 
[10]. However, in a later study evaluat-
ing the effect of 16.3 mg morphine and 
1.3 mg atropine, little change in res-
piratory rate was observed [11]. In yet 
another study, the exact same combi-
nation did produce an effect on pulse 
rate and a slight recovery of OIRD [12]. 
This is evidently somewhat surprising 
taken the high dose of morphine used 
in this study. Finally, in the first “ran-
domized controlled trial” (dated 1957) 
evaluating the effect of atropine on the 
ventilatory response to inhaled CO2 
(hypercapnic ventilatory response or 
HCVR), no beneficial effect was ob-
served on opioid-induced respiratory 
depression [23].
Caffeine
Caffeine, a methylxanthine alkaloid, 
was used historically to treat opium 
and morphine poisoning. Initially 
promising studies in rabbits showed 
a brisk increase in respiratory rate 
immediately following intravenous 
injection of caffeine to animals that 
were pretreated with morphine (See 
Figure 2) [14]. The first study that 
systematically evaluated the effect of 
caffeine in humans did not show an 
increase in respiratory rate, but did 
show a significant increase in alveolar 
ventilation and elimination of carbon 
dioxide (note that this was based on 
two subjects only) [10]. Subsequent 
studies could find some respiratory 
stimulation from caffeine but the ef-
fects were modest. For example, in a 
study comparing the effects of several 
stimulants on morphine-induced 
respiratory depression, caffeine pro-
duced just 17% increase in ventilation 
(whereas amphetamine more than 
doubled ventilation) [15]. The Ameri-
can anesthesiologist Jay Bellville stud-
ied the effect of 250 mg caffeine (the 
equivalent of five cups of coffee) on 
top of opioid depressed breathing in 
the early 1960s at Stanford University 
[16,17]. Only a clinically insignificant 
ventilatory effect was observed.
Although caffeine is no longer consid-
ered capable of reversing OIRD, it has 
proven to be a useful treatment option 
in neonatology, e.g. in premature neo-
nates with low birth weight. Caffeine 
reduces the incidence of bronchopul-
monary dysplasia, facilitates earlier 
discontinuation from the ventilator 
and improves the rate of survival with 
reduced neurodevelopmental disabil-
ity at 18 to 21 months in infants with 
low birth weight [18-21]. The mecha-
nism underlying the association of 
this favorable outcome and the use of 
caffeine is still unclear. Recent animal 
data show that caffeine possibly affects 
brainstem respiratory rhythmogenesis 
or causes hyperexcitability of motor 
networks involved in respiration by 
inhibiting phosphodiesterase [22, 23]. 
Interestingly the difference in efficacy 
of caffeine between neonates and 
adults could be related to maturation-
al changes in chemosensory responses 
[24].
Naloxone
In 1915 the German pharmacologist 
Julius Pohl discovered n-allyl-norco-
deine and observed that – although 
inactive when administered alone – it 
antagonized respiratory depression 
caused by morphine [25]. The value of 
this discovery was not recognized un-
til the early 1940s when (based on the 
finding of Pohl) N-allyl-normorphine 
or nalorphine was developed, a mor-
phine derivative [26-29]. This became 
the first agent to be widely applied 
as reversal agent of severe OIRD by 
restoring respiratory rate and tidal 
volume. Nalorphine was not only used 
to treat opioid overdose but also for 
the identification of a hidden opioid 
addiction [30]. Efforts to find an ideal 
morphine and nalorphine dose combi-
nation to produce analgesia with mini-
mal effects on respiration, led to the 
discovery that nalorphine also holds 
analgesic properties due to its opioid 
agonist-antagonist properties. Unfor-
tunately nalorphine causes dysphoric 
and psychomimetic side-effects limit-
ing its routine clinical use [31]. 
A suitable alternative was found in 
naloxone, an alkyl-derivative of norox-
ymorphone, first synthesized in 1960 
(see Figure 3). It is up to thirty times 
more effective in antagonizing OIRD 
than is nalorphine [32]. Naloxone is 
a non-selective competitive opioid 
antagonist at µ-, δ-, and κ-opioid 
receptors and reverses all pharmaco-
logical effects of opioids (including 
analgesia, sedation, respiratory de-
pression) in a dose-dependent fashion 
Figure 2. Respiratory tracing in the rabbit. An intravenous injection of 10 mg caffeine given at C causes an increase 
in respiratory rate at the background of morphine-induced respiratory depression. From Ref. 14.
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[33]. Naloxone is a lipophilic molecule 
and consequently rapidly passes the 
blood-brain-barrier with a near im-
mediate effect following intravenous 
administration. The elimination half-
life of naloxone is about 33 minutes 
[34]. For opioids with an elimination 
half-life >33 minutes (morphine, 
methadone) there is always the risk of 
re-narcotization and one should con-
sider a continuous naloxone infusion 
to treat severe intoxications. Naloxone 
is currently the treatment of choice for 
OIRD. The amount of naloxone neces-
sary to reverse respiratory depression 
depends on the opioid that requires 
antagonism (opioids differ in their 
affinity for the µ-opioid receptor and 
consequently in the ability of nalox-
one to disperse the opioid from the 
receptor) and the opioid dose [35]. In 
the perioperative setting, titration to 
effect is common practice using 40 µg 
bolus infusions.
 Aminophylline
The respiratory effects of amino-
phylline, a methylxanthine alike 
caffeine, are known since the 1960s, 
predominantly in the treatment of 
asthma. Aminophylline causes the 
translocation of calcium, inhibition 
of phosphodiesterase and blockade 
of the adenosine receptor [36]. These 
mechanisms are thought to contribute 
to the effects of aminophylline: bron-
chial muscle relaxation, improvement 
of diaphragm contractility, increase 
in the activity of the inspiratory mus-
cles, augmentation of the hypoxic 
ventilatory response and decrease of 
the incidence of postoperative apnea 
in preterm neonates [37-39]. Recently, 
the effect of 3 mg/kg aminophylline (3 
mg/kg) in propofol/remifentanil an-
esthesia was studied in adults. Amino-
phylline shortened the time to return 
of spontaneous breathing, increased 
tidal volumes and respiratory rate 
and increased BIS values compared to 
placebo [40]. However, aminophylline 
was also associated with a significant 
increase in heart rate, as already de-
scribed earlier [41]. 
Doxapram
Despite their respiratory effects, ana-
leptics are hardly ever used as respira-
tory stimulants, mainly because of 
their severe side effects (convulsion, 
hypertension) [42]. Newer synthetic 
analeptics, such as doxapram, were 
designed to specifically stimulate res-
piration without causing unwanted 
side effects [43-45]. In two studies in 
postoperative patients (performed in 
the mid-1960s), doxapram caused a 
moderate to intense increase in minute 
volume that peaked within 2.5 min 
but dissipated within 5 min [43, 44]. 
The most important mechanism of 
action of doxapram is inhibition of 
K+-channels expressed on the mem-
brane of peripheral chemoreceptors 
cells of the carotid bodies [46]. This 
leads to the local release of neuro-
transmitters (e.g. ATP, acetylcholine) 
that stimulate nerve endings of the 
sinus nerve, much alike the effect of 
hypoxia on the carotid bodies. The 
end-point of the K+-channel inhibi-
tion is a brisk hyperventilatory re-
sponse. Recently, it was shown 1 mg/
kg doxapram decreased the recovery 
period in perioperative patients after 
propofol/remifentanil anesthesia by 
optimizing (increasing) spontaneous 
breathing [40]. We recently studied 
the influence of doxapram on alfent-
anil-induced respiratory depression 
(arterial plasma concentrations 60-100 
ng/ml). Doxapram (total dose of 2.7 
mg/kg administered over 90 min) had 
no effect on ventilation [47]. However, 
doxapram had robust sympathico-
excitatory effects with an increase in 
cardiac output and heavy perspiration, 
which limited a further increase in 
dosing. We attribute the differences 
in study outcomes to the evident dif-
ferences in study methodology and 
setting (such as the differences in the 
opioid administration). Although 
doxapram is nowadays hardly ever 
used in adults, in preterm infants it is 
used to prevent apnea [48, 49]. Nega-
tive effects on cerebral oxygenation 
and long-term mental developments 
limit its use [48]. Still, doxapram has 
recently been reintroduced in preterm 
infants not responsive to methylxan-
thines. In a five year evaluation of the 
use of respiratory stimulants in two 
neonatal centers in the Netherlands, 
8% of premature infants < 32 weeks 
gestational age, were treated with 
doxapram [49]. In 2004, a Cochrane 
review of doxapram treatment for ap-
nea in preterm infants concluded that 
intravenous doxapram reduces apnea 
of prematurity and its success rate is 
comparable to methylxanthines [50]. 
A recent study found that doxapram 
[0.2 mg/kg/h, max 1.0 mg/kg/h] 
combined with methylxanthines, 
produced similar results compared 
to methylxanthines alone, showing 
an 80% reduction in apnea frequency 
with minimal side effects [51]. 
Almitrine
 Almitrine was developed in the 1970s. 
It can be administered intravenously 
and could be used perioperatively 
as a respiratory stimulant. Almitrine 
increases tidal volume and respira-
tory rate, especially under conditions 
of hypercapnia and hypoxia [52, 53]. 
Alike doxapram, almitrine stimulates 
afferent carotid body nerves mimick-
ing hypoxic stimulation of the periph-
eral chemoreceptors [54]. In addition 
to the effect exerted at the carotid 
bodies, almitrine improves the ventila-
tion-perfusion ratio and increase oxy-
genation in patients diagnosed with 
chronic obstructive pulmonary disease 
[55]. However, almitrine is considered 
unsuitable for clinical practice due to 
the peripheral neuropathy caused by 
it’s metabolites [52, 56]. 
Ampakines
Ampakines are drugs that modulate 
the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) re-
ceptors. AMPA receptors are involved 
Figure 3. First in man study displaying reversal of meperidine induced OIRD by naloxone. From Ref. 33.
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in glutamatergic transmission and are 
essential for maintaining respiratory 
rhythmogenesis in the brainstem. 
In a first study in humans, the ampa-
kine CX717 was tested on alfentanil-
induced respiratory depression [57]. 
CX717 increased respiratory frequen-
cy, hemoglobin oxygenation and VE55 
(minute volume at a fixed end-tidal 
pCO2 of 55 mmHg). Pain tolerance to 
heat and electrical stimuli did not dif-
fer between groups. However, subjects 
on CX717 reported increased sedation. 
Another interesting finding was that 
CX717 might be efficacious in main-
taining airway patency. Opioids do 
not only depress rhythmogenesis, but 
also depress hypoglossal nerve activity 
causing a decreased airway patency 
[58]. Cell patch recordings from hy-
poglossal motoneurons treated with 
the opioid DAMGO show that CX717 
counteracts the inhibitory opioid 
effect, however the exact mechanism 
remains unknown [59]. This suggests 
that CX717 might be a promising drug 
in the treatment/prevention of upper 
airway obstruction in patients with 
sleep-disordered breathing. 
GAL021
The latest addition and possibly most 
promising respiratory stimulant is 
GAL021 (a derivative of almitrine, 
however without harmful metabo-
lites). It inhibits calcium-activated 
potassium (BKCa) channels, thereby 
mimicking the effect of acute hypoxia 
at the carotid bodies. In the first in-
man trial, GAL021 increased ventila-
tion without causing any serious side 
effects [60]. We determined in our 
laboratory the effect of GAL021 on 
alfentanil-induced respiratory depres-
sion in healthy volunteers. During 
GAL021 infusion, respiratory rate and 
tidal volume increased significantly 
compared to placebo infusion, whilst 
analgesia and sedation were not af-
fected by the drug [61]. The pharma-
cokinetic-pharmacodynamic (PKPD) 
analysis of the data determined that 
GAL021 has a rapid onset of action and 
a very profound capability to reverse 
OIRD. However, the effect of GAL021 
is less pronounced in severe opioid-
induced respiratory depression, and 
higher dosages of GAL021 then only 
have a limited effect. These human 
data indicate that GAL021 is an excel-
lent drug for the adjuvant administra-
tion with opioids used for the treat-
ment of chronic pain [62].
Conclusions
Prevention of opioid induced respira-
tory depression has been a spearhead 
in the area of respiratory research in 
anesthesia. Over the years, an array of 
compounds have been examined, but 
rendered useless either due to clinical-
ly irrelevant effects or due to the pres-
ence of serious side effects. Currently, 
ampakines and the BKCa-channel 
blocker GAL021 are the most promis-
ing respiratory stimulants that prob-
ably may be used in the near future to 
prevent opioid induced respiratory 
depression.
Figure 4. Effect of GAL021 on opioid induced respiratory depression B: baseline (no drug, no added 
inspired carbon dioxide), C: the carbon dioxide clamp before any drug infusion, P1: low-dose alfen-
tanil (ALF) infusion before any GAL021 or placebo infusion (carbon dioxide-clamp plus ALF-low), 
P2: the combination of low-dose alfentanil and low-dose GAL021 or placebo (carbon dioxide-clamp 
plus ALF-low plus GAL021-low), P3: the combination of low-dose alfentanil with high-dose GAL021 
or placebo (carbon dioxide-clamp plus ALF-low plus GAL021-high), and P4: the combination of 
high-dose alfentanil with high-dose GAL021 or placebo (carbon dioxide-clamp plus ALF-high plus 
GAL021-high). Values are mean ± 95% CI. *P < 0.01 versus placebo. From Ref. 61.
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